June 2, 2010 | Johnson & Johnson's biotech unit, Centocor, is acquiring a small British company focused on finding treatments for a variety of pulmonary diseases. RespiVert has two candidates progressing into clinical development as treatments for asthma, COPD, and cystic fibrosis. New Jersey Business News